Therapeutic vitamin D conjugates
First Claim
Patent Images
1. A carrier-drug conjugate, comprising a targeting group that is a non-hormonal secosteroid vitamin D that is not hydroxylated at the carbon 1 position conjugated at the carbon 3 position to a protein having parathyroid hormone (PTH) activity, wherein said protein comprises an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
- 10.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.
204 Citations
26 Claims
- 1. A carrier-drug conjugate, comprising a targeting group that is a non-hormonal secosteroid vitamin D that is not hydroxylated at the carbon 1 position conjugated at the carbon 3 position to a protein having parathyroid hormone (PTH) activity, wherein said protein comprises an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
- 7. A pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a non-hormonal secosteroid vitamin D that is not hydroxylated at the carbon 1 position conjugated at the carbon 3 position via a scaffold to a protein having PTH activity, wherein said protein comprises an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
-
13. A pharmaceutical composition, comprising:
-
a) a protein having PTH activity, b) a targeting group that is a non-hormonal secosteroid vitamin D that is not hydroxylated at the carbon 1 position conjugated at the carbon 3 position, c) a scaffold stably attached to said targeting group, wherein after administration to a first test subject, said protein has a half-life measured by Enzyme Linked Immunosorbant Assay (ELISA) analysis of blood samples taken at a plurality of time points that is greater than a half-life of said protein administered to a second test subject without said stably attached scaffold moiety and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points, wherein said protein comprises an amino acid sequence with at east a 90% sequence identity to SEQ ID NO;
10. - View Dependent Claims (14, 15, 16, 17, 18, 19)
-
- 20. A carrier-drug conjugate, comprising a targeting group that is a secosteroid vitamin D that is not hydroxylated at the carbon 1 position non-releasably conjugated at the carbon 3 position to a protein having PTH activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
Specification